Mental Health May Impact Dermatologic Quality of Life

• by Andrea Surnit

• July 9, 2026

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

• by Jeffrey Crowley, Eingun James Song, Linda Stein-Gold, Paolo Gisondi, Christopher G. Bunick, Vishvas Garg, Emanuele Leoncini, Blair Kaplan, Richard Ta, Bang Truong, Dolly Sharma, Bruce Strober

• July 2, 2026

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

• by Kathryn Wighton

• June 30, 2026

• 3 min

Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study

• by Zhongyu Zhang, Bin Zhang, Yating Wen, Qian Hu, Wenjun Jiang, Jia Zhuo, Guangying Luo, Yuyi Wang

• July 6, 2026